Research programme: phosphodiesterase IVB inhibitors - Plexxikon

Drug Profile

Research programme: phosphodiesterase IVB inhibitors - Plexxikon

Alternative Names: PDE4B inhibitors research programme - Plexxikon; Phosphodiesterase IVB inhibitors research programme - Plexxikon; PLX 369; Research programme: PDE4B inhibitors - Plexxikon

Latest Information Update: 28 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Plexxikon
  • Class
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Chronic obstructive pulmonary disease; Inflammation

Most Recent Events

  • 04 Sep 2007 Lead development is ongoing
  • 16 Mar 2004 Plexxikon's PDE 4B inhibitor programme is available for partnering (
  • 16 Mar 2004 Preclinical trials in Chronic obstructive pulmonary disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top